Banff Centre Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2004



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Regulatory/Suppressor T Cells (D1)


Organizer(s) Ethan M. Shevach and Luciano Adorini
March 10—15, 2004
Banff Centre • Banff, Alberta Canada
Abstract Deadline: Nov 10, 2003
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Jan 12, 2004

Sponsored in part by the Director's Sponsor Fund

Summary of Meeting:
Although the concept of suppression mediated by T lymphocytes was originally proposed more than 30 years ago, recent studies in animal models of autoimmunity have rekindled interest in the existence of a subset of lymphocytes that specifically suppress immune responses. One population of naturally-occurring or endogenous T suppressor cells can be identified by co-expression of the CD4 and CD25 antigens. These cells suppress the activation of CD4 and CD8 T cells in vitro by an unknown cell-contact dependent mechanism. In vivo, these cells suppress autoimmune disease by both cell contact-dependent and suppressor cytokine-dependent pathways. Although these cells were originally described in the mouse, a population with identical phenotypic and functional properties has been identified in man. A second group of suppressor cells can be induced in vivo by oral exposure to antigen, by culture of T cells with cytokines (IL-10), or by pharmacologic manipulation of dendritic cell functions. These antigen-induced suppressors primarily inhibit T cell activation in vitro and in vivo by secreting suppressor cytokines. Determination of the cellular target and the molecular basis of CD4+CD25+ mediated suppression is a major area of current research. The nature of the physiologic ligand recognized by these cells is also unknown as is the breadth of their T cell repertoire. Suppressor/regulatory T cells have primarily been shown to inhibit animal models of autoimmune disease. However, recent studies have extended their range of activities to inhibition of tumor immunity, graft rejection, allergic disease, graft versus host disease, and acute and chronic infectious diseases. One critical area of future study will involve the development of protocols to enhance regulatory T cell function in vivo by pharmacologic means as such an approach should prove useful in autoimmunity, allergic disease, and graft rejection. Similarly, a related area will involve inhibition of regulatory T cell function, either transiently or permanently, by pharmacologic manipulation or treatment of animals or man with monoclonal antibodies specific for effector molecules on these cells. Protocols are now being developed for the adoptive immunotherapy of both CD4+CD25+ T cells that have been expanded in vitro and for suppressor cells that have been induced in vitro. These cells will be administered to patients with GVHD, graft rejection, and organ-specific and systemic autoimmune disease. This meeting will review all of the above issues and focus on the manipulation of regulatory T cell function in animal models of human disease as well as in disease in man.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


WEDNESDAY, MARCH 10

15:00—19:00
Registration

Eric Harvie Foyer
18:15—19:15
Refreshments

Eric Harvie Foyer
19:15—19:30
Orientation

Eric Harvie Theatre
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Eric Harvie Theatre
* Ethan M. Shevach, NIAID, National Institutes of Health, USA

Ronald N. Germain, NIAID, National Institutes of Health, USA
From Ts and I-J to Treg and CD25: From the Desert to the Promised Land?


THURSDAY, MARCH 11

07:00—08:00
Breakfast

Donald Cameron Hall
08:00—11:00
CD4+CD25+ T Cells: Properties and Function
Meeting has ended...abstracts no longer viewable online.

Eric Harvie Theatre
* Shimon Sakaguchi, Osaka University, Japan
Naturally Arising CD25+CD4+ Regulatory T Cells in Immunologic Tolerance: Foxp3, GiTR, IL-2/CO25 in Autoimmune Disease

Jocelyne Demengeot, Instituto Gulbenkian de Ciencia, Portugal
Function and Dynamic of Regulatory T Cells during Inflammatory Responses

Ethan M. Shevach, NIAID, National Institutes of Health, USA
CD4+CD25+ T Cells: Regulating the Regulator

Brian R. Champion, PsiOxus Therapeutics Ltd, UK
Peripheral T-Cell Regulation through the Notch Signaling Pathway

Dario A. A. Vignali, University of Pittsburgh School of Medicine, USA
Short Talk: Role of LAG-3 in Regulatory T Cell Function

09:20—09:40
Coffee Break

Eric Harvie Foyer
11:00—13:00
Poster Setup

Max Bell 251, 252, 253
13:00—22:00
Poster Viewing

Max Bell 251, 252, 253
16:30—17:00
Coffee & Snacks Available

Eric Harvie Foyer
17:00—19:15
Induced Regulatory T Cells: Characterization and Function
Meeting has ended...abstracts no longer viewable online.

Eric Harvie Theatre
* Maria Grazia Roncarolo, Stanford University School of Medicine, USA
Mechanisms Underlying the Induction and Effector Function of Tr1 Cells

Luciano Adorini, Intercept Pharmaceuticals, Inc., Italy
The Role of Dendritic Cells in the Induction of Regulatory T Cells

Catherine M. Hawrylowicz, King's College London, UK
Pharmacologic Induction of Regulatory T Cells

Richard A. Flavell, HHMI/Yale University School of Medicine, USA
Regulation of the Autoimmune Response by Suppressor T Cells and Cytokines

19:15—20:15
Social Hour

Max Bell Foyer
19:30—22:00
Poster Session 1

Max Bell 251, 252, 253
21:00—22:00
Workshop 1

Max Bell Auditorium
* Ethan M. Shevach, NIAID, National Institutes of Health, USA

* Luciano Adorini, Intercept Pharmaceuticals, Inc., Italy

Xuguang Tai, National Cancer Institute, National Institutes of Health, USA
Molecular Mapping of CD28 Costimulatory Signals Required for Treg Cell Generation

Sylvain Fisson, University of Evry Val d'Essonne, France
Homeostasis and Function of Islet Antigen-Specific Regulatory T Cells

Mindi R. Walker, Johnson and Johnson, USA
Induction of FoxP3 and Acquisition of T Regulatory Activity by Stimulated Human CD4+CD25- T Cells

Shuang Liang, University of Louisville Health Sciences Center, USA
CD4+CD25- Cells can be Converted into CD4+CD25+ Regulatory T Cells in the Periphery in the Absence of the Thymus

Joerg Ermann, Stanford University, USA
IL-2 Receptor Signaling in CD4+CD25+ Treg Cells


FRIDAY, MARCH 12

07:00—08:00
Breakfast

Donald Cameron Hall
08:00—11:00
Induction and Maintenance of Regulatory T Cells
Meeting has ended...abstracts no longer viewable online.

Eric Harvie Theatre
Andrew Caton, Wistar Institute, USA
CD4+ CD25+ Regulatory T Cell Selection

* Harald von Boehmer, Harvard Medical School, USA
In vivo Lifestyle of Regulatory T Cells

Thomas R. Malek, University of Miami School of Medicine, USA
Role of IL-2 in the Production and Maintenance of T Regulatory Cells

Marc A. Gavin, Amgen, USA
Short Talk: A Role for Phosphodiesterase 3B in the Homeostasis of CD4+CD25+ Regulatory T Cells

09:20—09:40
Coffee Break

Eric Harvie Foyer
11:00—13:00
Poster Setup

Max Bell 251, 252, 253
13:00—22:00
Poster Viewing

Max Bell 251, 252, 253
16:30—17:00
Coffee & Snacks Available

Eric Harvie Foyer
17:00—19:00
CD8+ Regulatory T Cells
Meeting has ended...abstracts no longer viewable online.

Eric Harvie Theatre
* Luciano Adorini, Intercept Pharmaceuticals, Inc., Italy

Yong-Jun Liu, Sanofi, USA
Human GITR-Ligand Preferentially Costimulate Cytotoxic CD8+ T Cells

Nicole Suciu-Foca, Columbia University, USA
CD8+CD28- Suppressor T Cells

Vipin Kumar, Torrey Pines Institute for Molecular Studies, USA
A Novel, Non-Classical MHC-Restricted CD8+ Regulatory T Cell Population Prevents Experimental Autoimmune Encephalomyelitis

Eli E. Sercarz, Torrey Pines Institute for Molecular Studies, USA
Short Talk: The Optimal Targets for Regulatory T Cells Are Driver T Cell Clones

19:00—20:00
Social Hour

Max Bell Foyer
19:30—22:00
Poster Session 2

Max Bell 251, 252, 253
21:00—22:00
Workshop 2

Max Bell Auditorium
* Luciano Adorini, Intercept Pharmaceuticals, Inc., Italy

* Ethan M. Shevach, NIAID, National Institutes of Health, USA

Vivian Tseveleki, Hellenic Pasteur Institute, Greece
Immunoregulatory Role of c-FLIPL in T Lymphocytes

Niklas Beyersdorf, Institute for Virology and Immunobiology, Germany
Expansion and Activation of Rat CD4+CD25+ Regulatory T Cells by Superagonistic CD28-Specific Monoclonal Antibodies

Kerstin Siegmund, Charité, Humboldt-Universitaet, Germany
Developmental Stage, Phenotype and Migration Distinguish Naïve- and Effector/Memory-Like CD4+ Regulatory T Cells

Alistair Noble, Rayne Institute, UK
CD8+, MHC Class I-Restricted Suppressor T Cells Secrete IFN-gamma and IL-10 but Act via Cell Contact Dependent Mechanisms

Chyi-Song Hsieh, Washington University, USA
Recognition of the Peripheral Self by Naturally-Arising CD25+ CD4+ T Cell Receptors


SATURDAY, MARCH 13

07:00—08:00
Breakfast

Donald Cameron Hall
08:00—11:00
Regulation of Immunity to Tumors and Infectious Agents
Meeting has ended...abstracts no longer viewable online.

Eric Harvie Theatre
Cornelis J. M. Melief, Leiden University Medical Center, Netherlands
Induction of Effective Tumor Immunity

Kingston H.G. Mills, Trinity College Dublin, Ireland
T Cell Mediated Regulation of Immunity to Bacteria

Yasmine Belkaid, NIAID, National Institutes of Health, USA
Regulatory T Cells Maintain Symbiosis between Immunity and Susceptibility to Parasite Infection

* Matthias G. von Herrath, Novo Nordisk and La Jolla Institute for Allergy and Immunology, USA
CD25+ Regulatory Cells in Viral Infections?

Weiping Zou, University of Michigan, USA
Short Talk: Specific Recruitment of Regulatory T Cells Fosters Immune Privilege in Ovarian Carcinoma

09:20—09:40
Coffee Break

Eric Harvie Foyer
11:00—13:00
Poster Setup

Max Bell 251, 252, 253
13:00—22:00
Poster Viewing

Max Bell 251, 252, 253
16:30—17:00
Coffee & Snacks Available

Eric Harvie Foyer
17:00—19:00
Regulatory T Cells in Human Disease Session Sponsored in part by the National Multiple Sclerosis Society
Meeting has ended...abstracts no longer viewable online.

Eric Harvie Theatre
Alexander H. Enk, Universitäts-Hautklinik Heidelberg, Germany
In vivo Function and Manipulation of Regulatory T Cells

* David A. Hafler, Yale University School of Medicine, USA
CD4+CD25+ Regulatory T Cells are Altered in Patients with Multiple Sclerosis

Arne N. Akbar, University College London, UK
Are Human CD4+CD25+ T Cells Derived From Effector Cells?

Francesco Annunziato, University of Florence, Italy
Short Talk: Effect of CD4+CD25+ or CD8+CD25+ FOXP3-Expressing Human T Regulatory Thymocytes on the Function of Autologous TH1 and TH2 Cells

19:00—20:00
Social Hour

Max Bell Foyer
19:30—22:00
Poster Session 3

Max Bell 251, 252, 253
21:00—22:00
Workshop 3

Max Bell Auditorium
* Luciano Adorini, Intercept Pharmaceuticals, Inc., Italy

* Ethan M. Shevach, NIAID, National Institutes of Health, USA

Salvatore Albani, University of California, San Diego, USA
Epitope-Specific Immunotherapy Induces Immune Deviation of Pro-Inflammatory T Cells in Rheumatoid Arthritis

Claudia Mauri, University College London, UK
The Generation and Function of Regulatory T Cells are Defective in Rheumatoid Arthritis: Reversal by Anti-TNFalpha Therapy

Rong-Fu Wang, Baylor College of Medicine, USA
Identification of Natural Ligands for Human CD4+ Regulatory T Cells: Implication for Immunotherapy

Susmit Suvas, Oakland University, USA
Role of CD4+CD25+ Regulatory T Cells in Herpes Viral Infection

Robert N. Barker, University of Aberdeen, UK
Immunosuppressive Regulatory T Cells in Hodgkin Lymphoma and Epstein-Barr Virus Infection


SUNDAY, MARCH 14

07:00—08:00
Breakfast

Donald Cameron Hall
08:00—11:00
Regulatory T Cell in Autoimmunity Session Sponsored in part by the Juvenile Diabetes Research Foundation International
Meeting has ended...abstracts no longer viewable online.

Eric Harvie Theatre
Kenneth S. Tung, University of Virginia, USA
Regional Lymph Node Regulation in 3dTx Mice

Fiona M. Powrie, University of Oxford, UK
Control of Immune Pathology by Regulatory T Cells

* Joan Goverman, University of Washington, USA
Suppression of Myelin-Specific T Cells In Vivo

Jeffrey A. Bluestone, University of California, San Francisco, USA
Antigen-Specificity and Function of Regulatory T Cells

Kristin V. Tarbell, NIDDK, National Institutes of Health, USA
Short Talk: CD25+ CD4+ T Cells, Expanded with Dendritic Cells Presenting a Single Autoantigenic Peptide, Block the Development of Diabetes in NOD Mice

09:20—09:40
Coffee Break

Eric Harvie Foyer
16:30—17:00
Coffee & Snacks Available

Eric Harvie Foyer
17:00—19:00
Regulatory T Cells in Transplantation and GVHD
Meeting has ended...abstracts no longer viewable online.

Eric Harvie Theatre
Kathryn J. Wood, University of Oxford, UK
Manipulation of Regulatory T Cell Function in Transplantation

Bruce R. Blazar, University of Minnesota, USA
The Role of CD4+CD25+ T Regulatory (Treg) Cells in Allogeneic Bone Marrow Transplantation (BMT)

* Herman Waldmann, University of Oxford, UK
Regulatory T Cells in Infectious Transplantion Tolerance

Sergio A. Quezada, University College London, UK
Short Talk: Visualizing Regulatory T Cell Control of Anti CD154-Induced Graft Tolerance in vivo

19:30—20:30
Social Hour

Donald Cameron Hall
20:30—23:30
Entertainment

Donald Cameron Hall

MONDAY, MARCH 15

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13CA105864-01




We gratefully acknowledge additional support for this conference from:

JDRF National Multiple Sclerosis Society

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676